CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Rosiglitazone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00265148
NCT00265148Phase 2Completed
CompareCT.gov

Effects of Avandia on Cognition and Cerebral Glucose Utilisation in Subjects With Mild to Moderate Alzheimer's Disease (AD).

GlaxoSmithKline·interventional·Posted Dec 14, 2005·Updated Nov 18, 2020

In Brief

A Phase 2 clinical trial evaluating Rosiglitazone and Placebo for Alzheimer's Disease. Completed, enrolled 80 participants across 15 sites in 3 countries.

Detailed Summary

This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesCanada, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 14, 2005
Enrollment StartMay 18, 2004
Primary CompletionJul 10, 2008
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 20.6 years ago

Interventions

Rosiglitazonedrug

Extended Release Tablets

Placeboother

Placebo dummy to match